Stuart M. Essig
STUART M. ESSIG, Ph.D., currently serves as managing director of Prettybrook Partners LLC, investing in medical technology companies. Prettybrook has approximately 20 active investments in a variety of companies, typically as a co-investor with institutional private equity.
Dr. Essig has been Integra LifeSciences Corporation’s (NASDAQ:IART) Chairman of the Board of Directors since 2012 and a Director since he joined Integra in 1997. He served as the company’s Chief Executive Officer from 1997 to 2012, building Integra into a global surgical products leader. During Stuart’s 20-year tenure with the company, Integra has grown revenues from approximately $15 million to over $1 billion and its market capitalization from approximately $100 million to a levered valuation of more than $4.5 billion. Share price during his tenure has increased from approximately $3 to over $50.
Before joining Integra, Dr. Essig was managing director of the medical technology practice at Goldman, Sachs & Co. He had ten years of broad healthcare experience at Goldman Sachs, serving as a senior merger and acquisitions advisor to a broad range of domestic and international medical technology, pharmaceutical and biotechnology clients.
Dr. Essig has chaired audit, compensation and nominating and governance committees, served as lead director, and participated in CEO succession processes, on the boards of numerous public companies, ranging in size from several hundred million dollars to $30 billion in levered market capitalization.
In addition to Integra, Dr. Essig currently serves on the Board of Directors of IDEXX Laboratories, Inc. (NASDAQ:IDXX), Owens & Minor, Inc. (NYSE:OMI) and SeaSpine Holdings Corporation (NASDAQ:SPNE). He is also the Chairman of the Board of Directors of private-equity backed Breg, Inc., a premium provider of high-value sports medicine products and services that advance patient care in orthopedics.
He is an executive-in-residence at Cardinal Partners and a venture partner at Wellington Partners Advisory AG, both venture capital firms. He also serves as a senior advisor to TowerBrook Capital Partners and Water Street Healthcare Partners. Dr. Essig is a founding investor member of Tigerlabs, a Princeton-based business accelerator.
He previously served on the Board of Directors of St. Jude Medical Corporation (NYSE:SJM) from 1999 to 2017, prior to its sale to Abbott Corporation. From 2005 until 2008 he served on the Board of Directors of Zimmer Holdings, Inc. (NYSE:ZMH), and from 1998 to 2002, he served on the Board of Directors of Vital Signs, Inc. (NASDAQ:VITL). He also served on the executive committee, nominating and governance committee, and as treasurer of ADVAMED, the Advanced Medical Technology Association.
Dr. Essig is also involved in several non-profit charitable organizations, including from time to time serving on their boards. Since 2012 he has served on the Board of Directors of Trenton-area non-profit, Isles, Inc. and since 2006 has served as a volunteer and fund raiser for the Children’s Brain Tumor Foundation (CBTF). In 2018, he was appointed to the CBTF’s President’s Advisory Council. He serves on the Leadership Council of the Princeton University School of Engineering and Applied Sciences, and the NACD Compensation Committee Chair Advisory Council.
Dr. Essig received an A.B. degree, and graduated with magna cum laude and Phi Beta Kappa honors from the Woodrow Wilson School of Public and International Affairs at Princeton University. He completed his M.B.A. and Ph.D. degrees in financial economics from the University of Chicago, Graduate School of Business.